Edgewise Therapeutics (EWTX) Current Leases (2022 - 2026)

Edgewise Therapeutics has disclosed Current Leases across 5 years of filings, most recently posting $1.0 million for Q1 2026.

• Current Leases for Q1 2026 came in at $1.0 million, up 1.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 million (up 1.6% YoY), and the FY2025 annual result was $1.0 million, up 1.81% from the prior year.
• Current Leases came in at $1.0 million for Q1 2026 at Edgewise Therapeutics, roughly flat from $1.0 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $1.0 million in Q1 2026 to a low of $104000.0 in Q2 2022.
• The 5-year median for Current Leases is $986000.0 (2024), against an average of $844062.5.
• Across the five-year window, Current Leases soared 738.46% in 2023 and increased 1.6% in 2026, its largest moves.
• Edgewise Therapeutics' Current Leases stood at $608000.0 in 2022, then soared by 61.18% to $980000.0 in 2023, then climbed by 1.63% to $996000.0 in 2024, then advanced by 1.81% to $1.0 million in 2025, then increased by 0.3% to $1.0 million in 2026.
• The last three Current Leases figures came in at $1.0 million (Q1 2026), $1.0 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.